Officially titled General Chapter <1136> was formally published in USP 38–NF 33. This chapter bridges the gap between analytical testing (which tells you that particles exist) and preventative strategy (which ensures they never appear in the first place).
USP General Chapter <1136> is far more than a glossary of storage terms—it is an enforceable standard that protects patients by ensuring that the drug tested in clinical trials reaches the pharmacy shelf in the same condition. For any organization involved in pharmaceutical packaging, warehousing, or distribution, mastering the definitions and operational expectations of <1136> is non-negotiable. usp -38 general chapter 1136-
Root cause analysis guided by finds:
The expiration date for repackaged units cannot exceed the manufacturer's original date or a maximum of 6 months (whichever is earlier) in the absence of specific stability data. and USP <
USP General Chapter establishes crucial standards for the packaging and repackaging of drug products into single-unit containers, focusing on safety, stability, and integrity. The guidelines emphasize selecting appropriate materials for barrier protection against environmental factors and ensuring precise labeling for traceability. focusing on safety
In the world of sterile pharmaceutical manufacturing, the naked eye is often the least reliable tool. For decades, the United States Pharmacopeia (USP) has provided rigorous standards to protect patients from subvisible and visible particulate contamination in parenteral drug products. While most industry professionals are familiar with USP <787> and USP <788> (Subvisible Particulate Matter in Therapeutic Protein Injections and Injections), a less discussed but equally critical chapter has emerged as a cornerstone of modern contamination control: .
Request the supplier's delamination potential study. If you use borosilicate glass vials, demand a "mapping study" of forming lubricants (which can crystalize into particles post-sterilization).